Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Semapimod

Drug Profile

Semapimod

Alternative Names: AXD-455; CN-1493; CNI 1493; CPSI-2364; Semapimod salt

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Picower Institute for Medical Research
  • Developer Cytokine PharmaSciences; GPC Biotech AG
  • Class Anti-inflammatories; Hydrazones; Small molecules
  • Mechanism of Action Cytokine inhibitors; HIV replication inhibitors; Immunomodulators; Interleukin 1 inhibitors; Interleukin 6 inhibitors; Mitogen-activated protein kinase inhibitors; Nitric oxide inhibitors; Raf kinase inhibitors; RNA inhibitors; Tumour necrosis factor alpha inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Autoimmune disorders; Inflammation
  • Discontinued Chemotherapy-induced damage; Crohn's disease; HIV infections; Pancreatitis; Psoriasis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top